Fix a date with Alexandra via the BIO platform or let us know when you’re there.
Have a great convention !

#BIO2023
#FrenchHealthcare

L’article Join MCE CARREL in Boston for BIO International Convention est apparu en premier sur MCE CARREL.

Based in Lyon, Mathilde Salavin works with a number of startup clients and public institutions in all areas of health and digital rights. Her practice covers the management of the clinical development of their drugs and devices as well as the negotiation of intellectual property contracts related to the transfer of their technologies.

She also regularly works alongside the firm’s private equity teams on contractual audit assignments.

Mathilde Salavin began her career in 2006 at SANOFI. She then moved within the group, before taking a position as legal manager within SANOFI Pasteur in 2014. She joined MCE Carrel in 2020 and participated in the opening of the Lyon office.

Mathilde will continue to bring her experience and expertise to our clients’ innovation projects.

Mathilde Salavin’s association with MCE CARREL AVOCATS is in line with the development policy and the dynamic approach desired by the firm to continue to be among the key legal players in the world of health, innovation and biotechnology.

L’article Mathilde Salavin nominated Partner of the firm ! est apparu en premier sur MCE CARREL.

Cédric HASCOET

Cédric Hascoet joined the Paris office of MCE CARREL in October 2022 after completing several internships in business law, in particular within the legal department of the Galeries Lafayette Group, as well as in the law firms BG2V and Didier Avocats. He supports the team in assisting clients with their corporate, fundraising and divestiture/acquisition needs.

Cédric obtained his Master 2 in Mergers and Acquisitions at the University of Paris-Saclay

Antoine ROBIN

Antoine ROBIN joined MCE Carrel in December 2022 after having acquired his first professional experiences in a legaltech as well as in the intellectual property and digital department of a law firm. Antoine will accompany innovative companies in their various legal issues.

Based in the Lyons office, Antoine gained his Master 2 degree in Intellectual property law at the Lumière University of Lyon II

L’article Welcome to Cédric Hascoet and Antoine Robin est apparu en premier sur MCE CARREL.

Armand DELIEGE

Armand joined the firm in April 2022 after more than 11 years as a contract & IP lawyer for a SATT and a national innovation research institute. Specialized in health and pharmaceutical law, NTIC and electronics, Armand has notably accompanied innovative projects from academic laboratories to the market, drafting and negotiating contracts in French and English. His training in international and European law is immensely relevant.

We wish Armand a very warm welcome.

L’article Welcome to our new recruit ! est apparu en premier sur MCE CARREL.

For the full story : GNUBIOTICS Press release

L’article Microbiome Innovation Strategic Partnership – GNUBIOTICS & ADM est apparu en premier sur MCE CARREL.

Alexandra CARREL and Jeremy PAPPALARDO  are leading a workshop on Term Sheet negotiation in conjunction with the Strasbourg-baesd incubator, SEMIA. The workshop will take place via web-conference, on Wednesday, 19th May in the morning.

Term Sheet negotiation:

• Case presentation
• Groupwork
• Feedback & conclusion

L’article MCE CARREL & SEMIA – Licensing Master Class est apparu en premier sur MCE CARREL.

VECT-HORUS ENTERS INTO COLLABORATION AND LICENSE AGREEMENT WITH ONO PHARMACEUTICAL CO., LTD.

2019/03/26

Vect-Horus S.A.S. (Marseille, France) announced today that Vect-Horus and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) signed a collaboration and license agreement, focused on the development of novel molecules targeting neurodegenerative diseases.

Under the agreement, Vect-Horus will receive research fees, success-based milestones on the research and development progress, as well as royalties on sales of the products.

Vect-Horus will apply its proprietary VECTrans® technology, which facilitates the transport of drugs into the brain, to ONO’s therapeutic molecules. Vect-Horus will utilize its expertise to conjugate these therapeutic molecules with its peptide vectors and demonstrate improved brain uptake and efficacy in animals. Ono will have worldwide exclusive rights to develop and commercialize any pharmaceutical products arising out of the drug discovery collaboration.

“We are delighted to partner with Ono, one of the oldest pharmaceutical companies in the world and an important developer of innovative drugs,” commented Alexandre Tokay, Chief Executive Officer and cofounder of Vect-Horus. “Our agreement with Ono strengthens our long-standing commitment to improve, using our technology, the brain delivery of therapeutic molecules and bring forward novel therapies that address critical unmet needs.”

About Vect-Horus Vect-Horus designs and develops vectors that facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain and tumors. Vect-Horus combines these different agents to its vectors that specifically target various receptors, allowing these agents to cross natural barriers (including the blood-brain-barrier) which limit access of therapeutic or imaging agents to their targets. The proof of concept of the technology has already been established in animal models using different vectorized molecules. Created in 2005, Vect-Horus is a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University), headed by Dr Michel Khrestchatisky, co-founder. To learn more about Vect-Horus, visit www.vect-horus.com. For more information about this press release, please contact Elodie Dormes, Business Development Manager of Vect-Horus: contact@vect-horus.com.

L’article INTERNATIONAL STRATEGIC AGREEMENT est apparu en premier sur MCE CARREL.